Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195710 · ClinicalTrials.gov registry record · Phase 1
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
A Phase 1 study of Metastases, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05195710: Recruiting Phase 1 study of Metastases, sponsored by M.D. Anderson Cancer Center.
NCT05195710 is a Phase 1 study of Metastases that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 130-participant average among 5 other Metastases trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05195710, a Phase 1 study of Metastases, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
Conditions Studied
Interventions
- DRUG Yttrium-90 (Y-90) resin microspheres
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
What NCT05195710 shows while recruiting
NCT05195710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 130-participant average among 5 other Metastases trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Metastases appearing as the primary indexed condition, and to 1 intervention - of which Yttrium-90 (Y-90) resin microspheres is the first listed.
NCT05195710 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05195710 about?
NCT05195710 is a clinical study titled "Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases". A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.
What is the current status of trial NCT05195710?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-11-16. Estimated completion is 2026-03-31.
What conditions does trial NCT05195710 study?
This clinical trial studies the following conditions: Metastases.
What interventions are being tested in trial NCT05195710?
The interventions under investigation include: Yttrium-90 (Y-90) resin microspheres (DRUG).
Who is sponsoring clinical trial NCT05195710?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195710 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
ACTIVE NOT RECRUITING · Phase 1
-
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
COMPLETED · Phase 1
-
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
COMPLETED · Phase 2
-
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
COMPLETED · Phase 2
-
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI